Cancer-focused genetic testing services firm NeoGenomics, based in Fort Myers, Fla., has named Singular Genomics President and COO Dave Daly to its board, according to a Nov. 14 Business Observer report.
Lab
Leonel Palatnik, 42, co-owner of Dallas-based Panda Conservation Group, a medical lab company, was sentenced to 82 months in prison for his role in a $73 million Medicare kickback scheme, according to a Nov. 9 Justice Department news release.
A now-closed New Jersey lab could have to pay hundreds of patients back for allegedly selling and administering fake COVID-19 tests, according to a Nov. 9 report by NBC affiliate WNBC.
An internal audit found that the University of Iowa's State Hygienic Laboratory left as much as $1.1 million on the table, thanks to inconsistent billing and document collection, according to a Nov. 8 report in The Gazette.
An Arkansas man who owned and managed several diagnostic testing laboratories was indicted in an alleged $100 million fraudulent billing scheme, the Justice Department said Nov. 3.
Advertisement
A joint venture between Los Angeles-based real estate firm Hatchspaces and Denver-based healthcare developer NexCore Group is building a life sciences wet lab in West Los Angeles, the companies said in a Nov. 3 news release.
The American Society for Clinical Pathology and the Joint Commission are kicking off a lab recognition program, the organizations said in an Oct. 27 news release.
Cambridge, Mass.-based blockchain platform Artifacts is partnering with South Bend, Ind.-based University of Notre Dame's Distributed Pharmaceutical Analysis Lab to combat the circulation of fake and substandard drugs, the university said in an Oct. 20 news release.
Nevada-based clinical laboratory MD Labs and two of its owners and co-founders will cumulatively pay between $11.6 million and $16 million to resolve allegations that they billed federal programs for medically unnecessary urine drug testing, according to a Justice Department…
Before the pandemic, many laboratories were already facing financial challenges due to severe downward pricing pressure caused by multi-year price cuts to the Medicare Part B clinical laboratory fee schedule.